NCT04577781 - A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

March 26, 2021

Study Completion Date

April 7, 2021

Conditions

Rheumatoid Arthritis

Interventions

DRUG

GLPG3970

GLPG3970 powder and solvent for oral solution to be reconstituted prior to use.

DRUG

Placebo

Placebo powder and solvent for oral solution to be reconstituted prior to use.

Trial Locations (9)

UMHAT Sv. Ivan Rilski EAD, Sofia

Medical Center Teodora, Rousse

SRI of Invalid Rehabilitation (EST Complex) of Vinnytsia M.I.Pyrogov NMU MOHU, Vinnytsia

GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine, Kharkiv

Medical Center Clinic of Modern Rheumatology, Zaporizhzhya

Aversi Clinic Ltd, Tbilisi

Consilium Medulla-multiprofile clinic Ltd, Tbilisi

Centrum Medyczne Grunwald, Poznan

Centrum Badan Klinicznych S.C., Poznan